Pulmonary Tuberculoses Clinical Trial
Official title:
Prevalence and Burden of Bronchiectasis in Tuberculous Patients
NCT number | NCT04085133 |
Other study ID # | 12345817 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 26, 2019 |
Est. completion date | April 1, 2020 |
Verified date | September 2019 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Bronchiectasis was described in the early 19th century by Laennec. Bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree
Status | Completed |
Enrollment | 50 |
Est. completion date | April 1, 2020 |
Est. primary completion date | January 1, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - 1-patients were diagnosed to have tuberculosis by sputum culture and gene x pert. 2-patients were diagnosed to have bronchiectasis after lab and radiological examination as well as clinical score. 3- patients diagnosed as bronchiectasis after history of tuberculosis or anti Tuberculosis treatment with positive or negative tuberculous culture in the time of research. Exclusion Criteria: - 1-patients presented with other Pulmonary diseases. 2-Chronic liver and renal disease . 3- Lung cancer and tumors. 4- patients were previously diagnosed as bronchiectasis . |
Country | Name | City | State |
---|---|---|---|
Egypt | Assiut unviresty | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To study prevalence of bronchiectasis in TB patients by case per year. | How many patients of TB will be diagnosed as abronchiectasis | One year | |
Secondary | To evaluate the burden of bronchiectasis in TB patients | by frequency of need for hospital admission per year, need for outpatient clinical visits per month and frequency of need for antimicrobial therapy other than anti-tuberculous treatment per month | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05017324 -
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
|
N/A | |
Completed |
NCT04207112 -
Economic Evaluation of New MDR TB Regimens
|
Phase 2/Phase 3 | |
Completed |
NCT04044001 -
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03159975 -
Safety and Immunogenicity Study of GX-70 in TB Patient
|
Phase 1 | |
Completed |
NCT02984579 -
Line Probe Assay Evaluation Study
|
N/A | |
Completed |
NCT05568368 -
Time-to-Detection in Culture of Mycobacterium Tuberculosis
|
||
Recruiting |
NCT04930978 -
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
|
||
Not yet recruiting |
NCT05477966 -
A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
|
||
Completed |
NCT05097638 -
Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.
|
||
Active, not recruiting |
NCT05045391 -
Pulmonary Aspergillosis in Tuberculosis Patients
|
||
Completed |
NCT02754765 -
Evaluating Newly Approved Drugs for Multidrug-resistant TB
|
Phase 3 | |
Active, not recruiting |
NCT03896685 -
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
|
Phase 3 |